

# Prostate Cancer™

U P D A T E

Conversations with Urologic Oncology Investigators  
Bridging the Gap between Research and Patient Care

**EDITOR**

Neil Love, MD

**INTERVIEWS**

Oliver Sartor, MD

Peter T Scardino, MD



Subscribe to Podcasts or download MP3s of this program at [ProstateCancerUpdate.com](http://ProstateCancerUpdate.com)

---

## *Prostate Cancer Update*

### A Continuing Medical Education Audio Series

---

#### STATEMENT OF NEED/TARGET AUDIENCE

Prostate cancer is one of the most rapidly evolving fields in urologic oncology. Published results from clinical trials lead to the emergence of new surgical and radiation therapy techniques and therapeutic agents, along with changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing urologist, radiation oncologist and medical oncologist must be well informed of these advances. To bridge the gap between research and practice, *Prostate Cancer Update* utilizes one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME program assists clinicians with the formulation of up-to-date clinical management strategies.

#### LEARNING OBJECTIVES

- Evaluate the clinical implications of emerging clinical trial data in prostate cancer screening, prevention and treatment, and incorporate these data into management strategies in the local and advanced disease settings.
- Counsel appropriately selected patients with prostate cancer about the availability of ongoing clinical trials.
- Inform patients with prostate cancer about the specific risks and benefits of local and systemic therapies.
- Provide individualized counseling to patients with prostate cancer regarding the choice and timing of endocrine therapy.
- Talk with appropriately selected patients with prostate cancer who are at high risk or have advanced disease about the risks and benefits of chemotherapy, including emerging data on taxane-based regimens.

#### PURPOSE OF THIS ISSUE OF *PROSTATE CANCER UPDATE*

The purpose of Issue 1 of *Prostate Cancer Update* is to provide information that helps clinicians integrate emerging clinical research data into management strategies for patients with prostate cancer.

#### ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

#### HOW TO USE THIS CME ACTIVITY

This CME activity contains an audio component. To receive credit, the participant should listen to the CD, review the CME information and complete the Post-test and Educational Assessment and Credit Form located in the back of this book or on our website, [ProstateCancerUpdate.com](http://ProstateCancerUpdate.com).

*This program is supported by educational grants from AstraZeneca Pharmaceuticals LP and Sanofi-Aventis.*

## CME INFORMATION

# Prostate Cancer™

U P D A T E

### FACULTY AFFILIATIONS

**Oliver Sartor, MD**

Associate Professor of Medicine  
Harvard Medical School  
Director of Clinical Trials  
(Genitourinary)  
Dana-Farber Cancer Institute  
Boston, Massachusetts

**Peter T Scardino, MD**

Chair, Department of Surgery  
Head, Prostate Cancer Program  
Florence and Theodore Baumritter/  
Enid Ancell Chair of Urologic Oncology  
Memorial Sloan-Kettering  
Cancer Center  
New York, New York

### CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the Research To Practice scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

**FACULTY** — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: **Dr Sartor** — Consulting Fees: Cytogen Corporation, Dendreon, GlaxoSmithKline, GPC Biotech, QLT Inc, Sanofi-Aventis; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Cytogen Corporation; Research Funds: GPC Biotech. **Dr Scardino** — Consulting Fees: STEBA Biotech NV.

**RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS** — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to report.

*This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.*

If you would like to discontinue your complimentary subscription to *Prostate Cancer Update*, please email us at [Info@ResearchToPractice.com](mailto:Info@ResearchToPractice.com), call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

QUESTIONS (PLEASE CIRCLE ANSWER):

1. The death rate from prostate cancer has been decreasing since the early 1990s.
  - a. True
  - b. False
2. Which of the following are FDA-approved antiandrogens?
  - a. Flutamide
  - b. Nilutamide
  - c. Bicalutamide
  - d. All of the above
  - e. None of the above
3. According to data published by Stephen Freedland in *JAMA*, patients with a rapid PSA doubling time after prostatectomy have an increased risk of prostate cancer mortality.
  - a. True
  - b. False
4. Memorial Sloan-Kettering published a study demonstrating that patients abundantly expressing the immunosuppressive molecule B7 on the surface of prostate cells are significantly \_\_\_\_\_ likely to experience prostate cancer recurrence.
  - a. Less
  - b. More
5. Abiraterone, a new hormonal therapy being evaluated in prostate cancer, blocks \_\_\_\_\_.
  - a. Androgen synthesis
  - b. Androgen receptors
  - c. Estrogen receptors
  - d. None of the above
6. Which chemotherapy agent has been found to prolong survival in men with hormone-refractory, metastatic prostate cancer?
  - a. Mitoxantrone
  - b. Docetaxel
  - c. Both a and b
  - d. None of the above
7. The Prostate Cancer Prevention Trial demonstrated that \_\_\_\_\_ significantly reduced the risk of prostate cancer.
  - a. Bicalutamide
  - b. Finasteride
  - c. Docetaxel
  - d. None of the above
8. Which of the following side effects are associated with docetaxel?
  - a. Nausea
  - b. Fatigue
  - c. Neuropathy
  - d. All of the above
  - e. None of the above
9. Docetaxel is currently being evaluated in patients with early-stage prostate cancer.
  - a. True
  - b. False
10. The RTOG is conducting a study evaluating radiation therapy in combination with hormone therapy followed by chemotherapy for patients with high-risk prostate cancer.
  - a. True
  - b. False
11. Which of the following side effects are associated with LHRH agonists?
  - a. Bone and muscle loss
  - b. Increased risk of diabetes
  - c. Fatigue
  - d. All of the above
  - e. None of the above

## EDUCATIONAL ASSESSMENT AND CREDIT FORM

### Prostate Cancer Update — Issue 1, 2008

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

#### PART ONE — Please tell us about your experience with this educational activity

**BEFORE completion of this activity, how would you characterize your level of knowledge on the following topics?**

4 = Expert 3 = Above average 2 = Competent 1 = Insufficient

Prognostic factors in prostate cancer .....4 3 2 1

Use of radiation therapy and hormonal therapy for high-risk prostate cancer.....4 3 2 1

Management of PSA recurrence after prostatectomy .....4 3 2 1

Role of chemotherapy in the treatment of prostate cancer .....4 3 2 1

Role of the novel antiandrogen abiraterone in the treatment of prostate cancer .....4 3 2 1

**AFTER completion of this activity, how would you characterize your level of knowledge on the following topics?**

4 = Expert 3 = Above average 2 = Competent 1 = Insufficient

Prognostic factors in prostate cancer .....4 3 2 1

Use of radiation therapy and hormonal therapy for high-risk prostate cancer.....4 3 2 1

Management of PSA recurrence after prostatectomy .....4 3 2 1

Role of chemotherapy in the treatment of prostate cancer .....4 3 2 1

Role of the novel antiandrogen abiraterone in the treatment of prostate cancer .....4 3 2 1

**Was the activity evidence based, fair, balanced and free from commercial bias?**

☐ Yes ☐ No

If no, please explain: .....

**Will this activity help you improve patient care?**

☐ Yes ☐ No ☐ Not applicable

If no, please explain: .....

**Did the activity meet your educational needs and expectations?**

☐ Yes ☐ No

If no, please explain: .....

**Please respond to the following LEARNER statements by circling the appropriate selection:**

4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = Learning objective not met N/A = Not applicable

**As a result of this activity, I will:**

- Evaluate the clinical implications of emerging clinical trial data in prostate cancer screening, prevention and treatment, and incorporate these data into management strategies in the local and advanced disease settings. ....4 3 2 1 N/M N/A
- Counsel appropriately selected patients with prostate cancer about the availability of ongoing clinical trials. ....4 3 2 1 N/M N/A
- Inform patients with prostate cancer about the specific risks and benefits of local and systemic therapies. ....4 3 2 1 N/M N/A
- Provide individualized counseling to patients with prostate cancer regarding the choice and timing of endocrine therapy. ....4 3 2 1 N/M N/A
- Talk with appropriately selected patients with prostate cancer who are at high risk or have advanced disease about the risks and benefits of chemotherapy, including emerging data on taxane-based regimens. ....4 3 2 1 N/M N/A

**What other practice changes will you make or consider making as a result of this activity?**

.....

EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

What additional information or training do you need on the activity topics or other oncology-related topics?

Additional comments about this activity:

May we include you in future assessments to evaluate the effectiveness of this activity?

☐ Yes ☐ No

**PART TWO — Please tell us about the faculty for this educational activity**

| 4 = Expert           |                             | 3 = Above average |   | 2 = Competent |                              | 1 = Insufficient |   |   |
|----------------------|-----------------------------|-------------------|---|---------------|------------------------------|------------------|---|---|
| Faculty              | Knowledge of subject matter |                   |   |               | Effectiveness as an educator |                  |   |   |
| Oliver Sartor, MD    | 4                           | 3                 | 2 | 1             | 4                            | 3                | 2 | 1 |
| Peter T Scardino, MD | 4                           | 3                 | 2 | 1             | 4                            | 3                | 2 | 1 |

Please recommend additional faculty for future activities:

Other comments about the faculty for this activity:

**REQUEST FOR CREDIT — Please print clearly**

Name: Specialty:

Degree:

☐ MD ☐ DO ☐ PharmD ☐ NP ☐ BS ☐ RN ☐ PA ☐ Other

Medical License/ME Number: Last 4 Digits of SSN (required):

Street Address: Box/Suite:

City, State, Zip:

Telephone: Fax:

Email:

Research To Practice designates this educational activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be \_\_\_\_\_ hour(s).

Signature: Date:

To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at [www.ProstateCancerUpdate.com/CME](http://www.ProstateCancerUpdate.com/CME).

# Prostate Cancer™

U P D A T E

|  |   |
|--|---|
| <b>Editor</b>                              | Neil Love, MD   |
| <b>Managing Editor</b>                     | Kathryn Ault Ziel, PhD  |
| <b>Scientific Director</b>                 | Richard Kaderman, PhD   |
| <b>Writers</b>                             | Lillian Sklaver Poltorack, PharmD<br>Douglas Paley<br>Clayton Campbell  |
| <b>Content Validation</b>                  | Margaret Peng<br>Erin Wall  |
| <b>Director, Creative and Copy Editing</b> | Aura Herrmann   |
| <b>Creative Manager</b>                    | Fernando Rendina  |
| <b>Graphic Designers</b>                   | Jessica Benitez<br>Jason Cunnius<br>Tamara Dabney<br>Claudia Munoz  |
| <b>Senior Production Editor</b>            | Alexis Oneca  |
| <b>Traffic Manager</b>                     | Tere Sosa   |
| <b>Copy Editors</b>                        | Dave Amber<br>Margo Harris<br>David Hill<br>Rosemary Hulce<br>Kirsten Miller<br>Pat Morrissey/Havlin<br>Carol Peschke<br>Susan Petrone  |
| <b>Production Manager</b>                  | Tracy Potter  |
| <b>Audio Production</b>                    | Frank Cesarano  |
| <b>Web Master</b>                          | John Ribeiro  |
| <b>Faculty Relations Manager</b>           | Melissa Vives   |
| <b>CME Director/CPD Director</b>           | Isabelle Tate   |
| <b>Contact Information</b>                 | Neil Love, MD<br>Research To Practice<br>One Biscayne Tower<br>2 South Biscayne Boulevard, Suite 3600<br>Miami, FL 33131<br>Fax: (305) 377-9998<br>Email: DrNeilLove@ResearchToPractice.com |
| <b>For CME/CNE Information</b>             | Email: CE@ResearchToPractice.com  |

---

Copyright © 2008 Research To Practice. All rights reserved.

The compact disc, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their

own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

# Prostate Cancer™

---

U P D A T E

Copyright © 2008 Research To Practice.  
This program is supported by educational grants from  
AstraZeneca Pharmaceuticals LP and Sanofi-Aventis.



Sponsored by Research To Practice.

Last review date: March 2008  
Release date: March 2008  
Expiration date: March 2009  
Estimated time to complete: 1.5 hours